IGC PHARMA INC (IGC) Fundamental Analysis & Valuation

NYSEARCA:IGC • US45408X3089

Current stock price

0.3019 USD
+0 (+0.3%)
At close:
0.3 USD
0 (-0.63%)
After Hours:

This IGC fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. IGC Profitability Analysis

1.1 Basic Checks

  • IGC had negative earnings in the past year.
  • In the past year IGC has reported a negative cash flow from operations.
  • IGC had negative earnings in each of the past 5 years.
  • IGC had a negative operating cash flow in each of the past 5 years.
IGC Yearly Net Income VS EBIT VS OCF VS FCFIGC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -5M -10M -15M

1.2 Ratios

  • With a Return On Assets value of -66.16%, IGC is not doing good in the industry: 71.88% of the companies in the same industry are doing better.
  • Looking at the Return On Equity, with a value of -79.66%, IGC is doing worse than 60.42% of the companies in the same industry.
Industry RankSector Rank
ROA -66.16%
ROE -79.66%
ROIC N/A
ROA(3y)-93.23%
ROA(5y)-72.05%
ROE(3y)-122.42%
ROE(5y)-91.4%
ROIC(3y)N/A
ROIC(5y)N/A
IGC Yearly ROA, ROE, ROICIGC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50 -100 -150

1.3 Margins

  • The Gross Margin of IGC (46.20%) is better than 63.54% of its industry peers.
  • In the last couple of years the Gross Margin of IGC has grown nicely.
  • The Profit Margin and Operating Margin are not available for IGC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 46.2%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.84%
GM growth 5Y75.22%
IGC Yearly Profit, Operating, Gross MarginsIGC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -1K -2K -3K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. IGC Health Analysis

2.1 Basic Checks

  • IGC does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • IGC has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for IGC has been increased compared to 5 years ago.
  • IGC has a worse debt/assets ratio than last year.
IGC Yearly Shares OutstandingIGC Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M
IGC Yearly Total Debt VS Total AssetsIGC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M

2.2 Solvency

  • Based on the Altman-Z score of -9.99, we must say that IGC is in the distress zone and has some risk of bankruptcy.
  • IGC has a Altman-Z score of -9.99. This is in the lower half of the industry: IGC underperforms 72.40% of its industry peers.
  • A Debt/Equity ratio of 0.02 indicates that IGC is not too dependend on debt financing.
  • IGC has a Debt to Equity ratio (0.02) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Altman-Z -9.99
ROIC/WACCN/A
WACC9.17%
IGC Yearly LT Debt VS Equity VS FCFIGC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10M -10M 20M 30M

2.3 Liquidity

  • IGC has a Current Ratio of 1.32. This is a normal value and indicates that IGC is financially healthy and should not expect problems in meeting its short term obligations.
  • The Current ratio of IGC (1.32) is worse than 76.56% of its industry peers.
  • IGC has a Quick Ratio of 1.32. This is a bad value and indicates that IGC is not financially healthy enough and could expect problems in meeting its short term obligations.
  • IGC has a worse Quick ratio (0.89) than 79.17% of its industry peers.
Industry RankSector Rank
Current Ratio 1.32
Quick Ratio 0.89
IGC Yearly Current Assets VS Current LiabilitesIGC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M 25M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. IGC Growth Analysis

3.1 Past

  • IGC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 58.49%, which is quite impressive.
  • IGC shows a decrease in Revenue. In the last year, the revenue decreased by -6.51%.
  • IGC shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -20.77% yearly.
EPS 1Y (TTM)58.49%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%11.06%
Revenue 1Y (TTM)-6.51%
Revenue growth 3Y47.02%
Revenue growth 5Y-20.77%
Sales Q2Q%-53.64%

3.2 Future

  • Based on estimates for the next years, IGC will show a quite strong growth in Earnings Per Share. The EPS will grow by 10.20% on average per year.
  • Based on estimates for the next years, IGC will show a small growth in Revenue. The Revenue will grow by 0.24% on average per year.
EPS Next Y12.09%
EPS Next 2Y10.2%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-11.13%
Revenue Next 2Y0.24%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
IGC Yearly Revenue VS EstimatesIGC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2M 4M 6M
IGC Yearly EPS VS EstimatesIGC Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 -0.05 -0.1 -0.15 -0.2

More info and screens

Find the best growth stocksShow best growing peers

0

4. IGC Valuation Analysis

4.1 Price/Earnings Ratio

  • IGC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year IGC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IGC Price Earnings VS Forward Price EarningsIGC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IGC Per share dataIGC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.05 -0.05

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10.2%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. IGC Dividend Analysis

5.1 Amount

  • No dividends for IGC!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

IGC Fundamentals: All Metrics, Ratios and Statistics

IGC PHARMA INC

NYSEARCA:IGC (4/10/2026, 8:04:00 PM)

After market: 0.3 0 (-0.63%)

0.3019

+0 (+0.3%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-02
Earnings (Next)06-25
Inst Owners20.11%
Inst Owner Change0%
Ins Owners3.92%
Ins Owner Change-0.22%
Market Cap28.04M
Revenue(TTM)1.11M
Net Income(TTM)-6.45M
Analysts80
Price Target4.08 (1251.44%)
Short Float %0.79%
Short Ratio1.86
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-13.54%
Min Revenue beat(2)-26.7%
Max Revenue beat(2)-0.38%
Revenue beat(4)2
Avg Revenue beat(4)-4.75%
Min Revenue beat(4)-26.7%
Max Revenue beat(4)7.13%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)10.34%
PT rev (3m)10.34%
EPS NQ rev (1m)4.38%
EPS NQ rev (3m)-30.41%
EPS NY rev (1m)0%
EPS NY rev (3m)-25.9%
Revenue NQ rev (1m)-20.31%
Revenue NQ rev (3m)-20.31%
Revenue NY rev (1m)-15.05%
Revenue NY rev (3m)-15.05%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 25.35
P/FCF N/A
P/OCF N/A
P/B 3.46
P/tB 8.73
EV/EBITDA N/A
EPS(TTM)-0.08
EYN/A
EPS(NY)-0.07
Fwd EYN/A
FCF(TTM)-0.07
FCFYN/A
OCF(TTM)-0.06
OCFYN/A
SpS0.01
BVpS0.09
TBVpS0.03
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -66.16%
ROE -79.66%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 46.2%
FCFM N/A
ROA(3y)-93.23%
ROA(5y)-72.05%
ROE(3y)-122.42%
ROE(5y)-91.4%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.84%
GM growth 5Y75.22%
F-Score2
Asset Turnover0.11
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 125.74%
Cap/Sales 64.92%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.32
Quick Ratio 0.89
Altman-Z -9.99
F-Score2
WACC9.17%
ROIC/WACCN/A
Cap/Depr(3y)84.26%
Cap/Depr(5y)139.57%
Cap/Sales(3y)48.11%
Cap/Sales(5y)101.2%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)58.49%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%11.06%
EPS Next Y12.09%
EPS Next 2Y10.2%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-6.51%
Revenue growth 3Y47.02%
Revenue growth 5Y-20.77%
Sales Q2Q%-53.64%
Revenue Next Year-11.13%
Revenue Next 2Y0.24%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y5.37%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y9.51%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y11.44%
OCF growth 3YN/A
OCF growth 5YN/A

IGC PHARMA INC / IGC Fundamental Analysis FAQ

What is the fundamental rating for IGC stock?

ChartMill assigns a fundamental rating of 1 / 10 to IGC.


What is the valuation status of IGC PHARMA INC (IGC) stock?

ChartMill assigns a valuation rating of 0 / 10 to IGC PHARMA INC (IGC). This can be considered as Overvalued.


What is the profitability of IGC stock?

IGC PHARMA INC (IGC) has a profitability rating of 1 / 10.


What is the earnings growth outlook for IGC PHARMA INC?

The Earnings per Share (EPS) of IGC PHARMA INC (IGC) is expected to grow by 12.09% in the next year.